FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3168297092> ?p ?o ?g. }

• W3168297092 abstract "Background: Mineralocorticoid receptor antagonists (MRA) improve outcomes in chronic kidney disease (CKD) and acute myocardial infarction (AMI) patients. However, the lack of evidence regarding long-term clinical outcomes in the use of MRA, including spironolactone, in patients with AMI combined with CKD. Objectives: This study aimed to investigate whether spironolactone could significantly reduce the risk of all-cause mortality and re-admission in patients with AMI and CKD. Methods: In this single center, observational, retrospective, registry based clinical study, a total of 2,465 AMI patients were initially screened; after excluding patients with estimated glomerular filtration rate more than 60 ml/min/1.73 m 2 , 360 patients in the standard treatment group and 200 patients in the spironolactone group met the criteria. All enrolled patients follow-up for 30 months. The primary outcomes were all-cause mortality and re-admission. The key safety outcome was hyperkalemia rates during the 30 months follow-up period. Results: 160 (44.4%) and 41 (20.5%) patients in the standard treatment and spironolactone groups died, respectively [hazard ratio (HR): 0.389; 95% confidence interval (CI): 0.276–0.548; p &lt; 0.001]. Re-admission occurred in 217 (60.3%) and 95 (47.5%) patients in the standard treatment and spironolactone groups, respectively (HR: 0.664; 95% CI: 0.522–0.846; p = 0.004). The spironolactone group was divided into two based on the daily dose, low dose group (no more than 40 mg) and high dose group (more than 40 mg); the differences in the mortality rate between low dose group (16.7%) and the standard treatment group (44.4%) (HR: 0.309; 95% CI: 0.228–0.418; p &lt; 0.001) and high dose group (34.1%) (HR: 0.429; 95% CI: 0.199–0.925; p = 0.007) were significant. The differences in re-hospitalization rate between low dose group (43.6%) and the standard treatment group (60.3%) (HR: 0.583; 95% CI: 0.457–0.744; p &lt; 0.001) and high dose group (61.4%) (HR: 0.551; 95% CI: 0.326–0.930; p = 0.007) was significant. Hyperkalemia occurred in 18 (9.0%) and 18 (5.0%) patients in the spironolactone group and standard treatment group, respectively (HR: 1.879; 95% CI: 0.954–3.700; p = 0.068). Whereas, Hyperkalemia occurred in high dose group (20.5%) significantly more often than in the standard treatment group ( p &lt; 0.001) and low dose group (5.8%) ( p = 0.003). Conclusion: Using MRA, such as spironolactone, may substantially reduce the risk of both all-cause mortality and re-admission in patients with AMI and CKD; the use of low-dose spironolactone has the best efficacy and safety. However, this was a relatively small sample size, single center, observational, retrospective, registry based clinical study and further prospective evaluation in adequately powered randomized trials were needed before further use of spironolactone in AMI with CKD population." @default.
• W3168297092 created "2021-06-22" @default.
• W3168297092 creator A5002929656 @default.
• W3168297092 creator A5004511332 @default.
• W3168297092 creator A5007591506 @default.
• W3168297092 creator A5032252723 @default.
• W3168297092 creator A5038042386 @default.
• W3168297092 creator A5055435856 @default.
• W3168297092 creator A5058676060 @default.
• W3168297092 creator A5058768535 @default.
• W3168297092 creator A5059876880 @default.
• W3168297092 creator A5066654480 @default.
• W3168297092 creator A5073597282 @default.
• W3168297092 creator A5081435359 @default.
• W3168297092 creator A5082999787 @default.
• W3168297092 creator A5084188794 @default.
• W3168297092 date "2021-05-31" @default.
• W3168297092 modified "2023-10-18" @default.
• W3168297092 title "Spironolactone Improves the All-Cause Mortality and Re-Hospitalization Rates in Acute Myocardial Infarction with Chronic Kidney Disease Patients" @default.
• W3168297092 cites W2011500672 @default.
• W3168297092 cites W2020811647 @default.
• W3168297092 cites W2031706977 @default.
• W3168297092 cites W2043296060 @default.
• W3168297092 cites W2046326478 @default.
• W3168297092 cites W2057886201 @default.
• W3168297092 cites W2060297801 @default.
• W3168297092 cites W2082069148 @default.
• W3168297092 cites W2097773873 @default.
• W3168297092 cites W2111945961 @default.
• W3168297092 cites W2119620107 @default.
• W3168297092 cites W2123021239 @default.
• W3168297092 cites W2133808321 @default.
• W3168297092 cites W2136796090 @default.
• W3168297092 cites W2145632027 @default.
• W3168297092 cites W2146105386 @default.
• W3168297092 cites W2152072062 @default.
• W3168297092 cites W2164152578 @default.
• W3168297092 cites W2164705414 @default.
• W3168297092 cites W2323458614 @default.
• W3168297092 cites W2340705475 @default.
• W3168297092 cites W2341265724 @default.
• W3168297092 cites W2755505479 @default.
• W3168297092 cites W2756001500 @default.
• W3168297092 cites W2803805547 @default.
• W3168297092 cites W2901393632 @default.
• W3168297092 cites W2908332469 @default.
• W3168297092 cites W2912461571 @default.
• W3168297092 cites W2915695440 @default.
• W3168297092 cites W30493569 @default.
• W3168297092 cites W4245485459 @default.
• W3168297092 doi "https://doi.org/10.3389/fphar.2021.632978" @default.
• W3168297092 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8201517" @default.
• W3168297092 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34135751" @default.
• W3168297092 hasPublicationYear "2021" @default.
• W3168297092 type Work @default.
• W3168297092 sameAs 3168297092 @default.
• W3168297092 citedByCount "3" @default.
• W3168297092 countsByYear W31682970922022 @default.
• W3168297092 crossrefType "journal-article" @default.
• W3168297092 hasAuthorship W3168297092A5002929656 @default.
• W3168297092 hasAuthorship W3168297092A5004511332 @default.
• W3168297092 hasAuthorship W3168297092A5007591506 @default.
• W3168297092 hasAuthorship W3168297092A5032252723 @default.
• W3168297092 hasAuthorship W3168297092A5038042386 @default.
• W3168297092 hasAuthorship W3168297092A5055435856 @default.
• W3168297092 hasAuthorship W3168297092A5058676060 @default.
• W3168297092 hasAuthorship W3168297092A5058768535 @default.
• W3168297092 hasAuthorship W3168297092A5059876880 @default.
• W3168297092 hasAuthorship W3168297092A5066654480 @default.
• W3168297092 hasAuthorship W3168297092A5073597282 @default.
• W3168297092 hasAuthorship W3168297092A5081435359 @default.
• W3168297092 hasAuthorship W3168297092A5082999787 @default.
• W3168297092 hasAuthorship W3168297092A5084188794 @default.
• W3168297092 hasBestOaLocation W31682970921 @default.
• W3168297092 hasConcept C126322002 @default.
• W3168297092 hasConcept C159641895 @default.
• W3168297092 hasConcept C164705383 @default.
• W3168297092 hasConcept C167135981 @default.
• W3168297092 hasConcept C189135053 @default.
• W3168297092 hasConcept C207103383 @default.
• W3168297092 hasConcept C2776379505 @default.
• W3168297092 hasConcept C2778198053 @default.
• W3168297092 hasConcept C2778525890 @default.
• W3168297092 hasConcept C2778653478 @default.
• W3168297092 hasConcept C2780243291 @default.
• W3168297092 hasConcept C44249647 @default.
• W3168297092 hasConcept C500558357 @default.
• W3168297092 hasConcept C71924100 @default.
• W3168297092 hasConceptScore W3168297092C126322002 @default.
• W3168297092 hasConceptScore W3168297092C159641895 @default.
• W3168297092 hasConceptScore W3168297092C164705383 @default.
• W3168297092 hasConceptScore W3168297092C167135981 @default.
• W3168297092 hasConceptScore W3168297092C189135053 @default.
• W3168297092 hasConceptScore W3168297092C207103383 @default.
• W3168297092 hasConceptScore W3168297092C2776379505 @default.
• W3168297092 hasConceptScore W3168297092C2778198053 @default.
• W3168297092 hasConceptScore W3168297092C2778525890 @default.
• W3168297092 hasConceptScore W3168297092C2778653478 @default.
• W3168297092 hasConceptScore W3168297092C2780243291 @default.
• W3168297092 hasConceptScore W3168297092C44249647 @default.

• next